T0	Participants 50 149	advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials:
T1	Participants 255 369	advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials.
T2	Participants 912 966	1203 patients treated on 4 randomized clinical trials.
T3	Participants 1684 1735	patients with advanced/recurrent endometrial cancer